VIZZUTTI, FRANCESCO
 Distribuzione geografica
Continente #
NA - Nord America 4.997
EU - Europa 3.301
AS - Asia 655
AF - Africa 25
SA - Sud America 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.983
Nazione #
US - Stati Uniti d'America 4.987
RU - Federazione Russa 1.134
PL - Polonia 804
IE - Irlanda 348
SE - Svezia 318
IT - Italia 306
HK - Hong Kong 222
SG - Singapore 217
CN - Cina 96
UA - Ucraina 96
DE - Germania 95
FI - Finlandia 72
GB - Regno Unito 49
CH - Svizzera 42
JO - Giordania 41
IN - India 40
TR - Turchia 19
VN - Vietnam 17
CI - Costa d'Avorio 14
BE - Belgio 12
FR - Francia 11
CA - Canada 10
RO - Romania 9
SC - Seychelles 8
NL - Olanda 4
BR - Brasile 3
EU - Europa 2
ID - Indonesia 2
AT - Austria 1
DZ - Algeria 1
EG - Egitto 1
KR - Corea 1
TZ - Tanzania 1
Totale 8.983
Città #
Santa Clara 873
Warsaw 804
Fairfield 665
Chandler 390
Dublin 348
Ashburn 297
Woodbridge 277
Cambridge 271
Seattle 260
Houston 233
Wilmington 225
Singapore 172
Jacksonville 162
Hong Kong 150
Ann Arbor 126
Lawrence 90
Altamura 86
Princeton 81
Florence 69
Boardman 62
Boston 50
Moscow 47
Buffalo 45
Bern 42
Medford 42
Mumbai 37
San Diego 36
Beijing 30
Shanghai 21
New York 20
Izmir 19
Los Angeles 18
Milan 16
Falls Church 15
Abidjan 14
Kent 14
Brussels 12
Dong Ket 10
Norwalk 10
Timisoara 9
Yubileyny 9
Andover 8
Bremen 8
Frankfurt Am Main 8
Phoenix 8
Rome 8
Hillsboro 7
Auburn Hills 6
London 6
Toronto 6
West Jordan 6
Bologna 5
Helsinki 5
Dearborn 4
Modena 4
Nanjing 4
Redmond 4
Tappahannock 4
Genova 3
Menlo Park 3
Montalbano Jonico 3
Munich 3
Ottawa 3
Riardo 3
Trumbull 3
Villaricca 3
Aosta 2
Arnsberg 2
Banda Aceh 2
Catania 2
Cesena 2
Chiswick 2
Cortona 2
Laurel 2
Marechal Candido Rondon 2
Osimo 2
Padova 2
Palermo 2
Terni 2
Venice 2
Verona 2
Arezzo 1
Bolzano 1
Bovisio-Masciago 1
Caldogno 1
Campagnola Emilia 1
Dallas 1
Dar es Salaam 1
Evesham 1
Grevenbroich 1
Gunzenhausen 1
Hangzhou 1
Hanover 1
Heze 1
Huntsville 1
Incisa 1
Iowa City 1
Kilburn 1
Leawood 1
Livorno 1
Totale 6.331
Nome #
Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis 268
Consensus conference on TIPS management: Techniques, indications, contraindications 268
Aggressive gastric carcinoma producing alpha-fetoprotein: a case report and review of the literature. 252
Acute on chronic liver failure: From pathophysiology to clinical management. 228
Transjugular Intrahepatic Portosystemic Shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: A real-life, case-control study 208
Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis 200
Anatomy and vascular biology of the cells in the portal circulation 191
Acute viral hepatitis increases liver stiffness values measured by transient elastography 155
Low molecular weight heparin does not increase bleeding and mortality post-endoscopic variceal band ligation in cirrhotic patients 150
Thrombopoietin stimulates migration and activates multiple signaling pathways in hepatoblastoma cells. 136
Prevention of severe toxic liver injury and oxidative stress in MCP-1-deficient mice 135
Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C 133
Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells 132
Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. 131
Review article: the pathogenesis of fibrosis in non-alcoholic steatohepatitis. 128
THE ACTIN CYTOSKELETON AS A NOVEL TARGET OF AMP-ACTIVATED PROTEIN KINASE (AMPK) IN HEPATIC STELLATE CELLS 128
Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. 127
Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease 125
ADMA correlates with portal pressure in patients with compensated cirrhosis. 124
Elevated plasma levels of urotensin II do not correlate with systemic haemodynamics in patients with cirrhosis. 119
Ascites and hepatorenal syndrome 118
Lack of CC chemokine ligand 2 differentially affects inflammation and fibrosis according to the genetic background in a murine model of steatohepatitis. 117
Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study 117
COMPARISON BETWEEN HEPATIC VENOUS PRESSURE GRADIENT (HVPG) AND LIVER STIFFNESS MEASUREMENT (LSM) IN PATIENTS WITH HCV-RELATED FIBROSIS/CIRRHOSIS 114
Performance of Doppler ultrasound in the prediction of severe portal hypertension in hepatitis C virus-related chronic liver disease 113
Farnesyltransferase inhibitor ABT-100 is a potent liver cancer chemopreventive agent 113
Cardiovascular effects of canrenone in patients with preascitic cirrhosis 111
Cellular and molecular basis of fibrogenesis in NASH 110
Transient elastography for the assessment of liver fibrosis in patients with chronic viral hepatitis: The missing tool? 109
Altered clot formation and lysis are associated with increased fibrinolytic activity in ascites in patients with advanced cirrhosis 107
Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis 107
Transient elastography (TE) is more effective for the identification of HCV patients with advanced (F3-F4) rather than significant (F2-F4) liver fibrosis 107
Elastography for the non-invasive assessment of liver disease: limitations and future developments 105
Uveitis in autoimmune hepatitis: a case report. 102
Increased plasma carbon monoxide in patients with viral cirrhosis and hyperdynamic circulation. 102
Hepato-systemic gradient of carbon monoxide in cirrhosis. 102
Transient elastography (TE) is more effective for the identification of HCV patients with severe (> F3) rather than significant (> F2) liver fibrosis 99
n-3 polyunsaturated fatty acids worsen inflammation and fibrosis in experimental nonalcoholic steatohepatitis. 98
Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice 97
PORTAL HYPERTENSION SECONDARY TO MYELOFIBROSIS A STUDY OF THREE CASES. 96
Alcohol use disorder and liver transplant: new perspectives and critical issues 96
Fibrosis and cirrhosis reversibility: clinical features and implications 95
Vascular disorders of the liver: recommendations from the Italian Association for the Study of the Liver (AISF) ad hoc committee. 94
Clinical evaluation of disease progression in chronic liver disease: towards an integrated system? 94
Non invasive diagnosis of portal hypertension in cirrhotic patients. 91
Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis 91
Elastography, Spleen Size, and Platelet Count Identify Portal Hypertension in Patients With Compensated Cirrhosis. 91
Transjugular intrahepatic portosystemic shunt (TIPS): current indications and strategies to improve the outcomes 91
Effects of dietary supplementation with arachidonic acid on platelet and renal function in patients with cirrhosis. 90
Hemodynamic, renal and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis 89
Super-resolution microscopy reveals an altered fibrin network in cirrhosis: The key role of oxidative stress in fibrinogen structural modifications 89
Characterization of lymphocyte subsets in ascitic fluid and peripheral blood of decompensated cirrhotic patients with chronic hepatitis C and alcoholic liver disease: A pivotal study 88
EVIDENCE FOR A PATHOGENETIC ROLE OF ASYMMETRIC DIMETHYLARGININE (ADMA) IN CIRRHOTIC PORTAL HYPERTENSION. 88
Liver failure complicating segmental hepatic ischaemia induced by a PTFE-coated TIPS stent. 86
Performance of ELF Serum Markers in Predicting Fibrosis Stage in Pediatric Non-Alcoholic Fatty Liver Disease. 85
Update on ascites and hepatorenal syndrome 83
Adipokines and liver fibrosis.Eur Rev Med Pharmacol 82
LIVER STIFFNESS MEASUREMENT (LSM) IS ABLE TO PREDICT SEVERE PORTAL HYPERTENSION IN PATIENTS WITH HCV-RELATED ADVANCED CHRONIC LIVER DISEASE 82
Liver Stiffness, a non-invasive marker of liver disease: a core study group report. 81
The Metabolic Syndrome and Chronic Liver Disease. 81
Reversible factors in portal hypertension. 79
Impaired sympathetic regulation of cerebral blood flow in patients with cirrhosis of the liver. 78
Response to letter by R. Mookerjee and R. Jalan [2] 78
Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study 77
Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. 75
Etiology, management, and outcome of the Budd-Chiari syndrome. 74
Paradoxical embolization in TIPS: take a closer look to the heart. 74
Silybin, a component of sylimarin, exert anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells 73
 Glycogenic hepatopathy associated with type 1 diabetes mellitus as a cause of recurrent liver damage. 72
Expanding the severity range of polytetrafluoroethylene-related hepatic outflow occlusion. 71
Effect of rituximab on advanced liver disease in patients with HCV-related mixed cryoglobulinemia. 65
Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease. 63
Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model 62
Technology insights: non invasive assessment of liver fibrosis by biochemical scores and elastography. 59
Small diameter H-graft porta-caval shunt performed at different stages of liver disease 55
DIURETIC AND NATRIURETIC EFFECTS OF LONG-TERM ALBUMIN INFUSION IN PATIENTS WlTH CIRRHOSIS AND ASCITES: A RANDOMISED CONTROLLED STUDY 54
Transjugular intrahepatic Porto-systemic shunt positively influences the composition and metabolic functions of the gut microbiota in cirrhotic patients 54
Acites due to pericardial cyst 53
Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: a long-term follow-up study 50
Portosystemic shunt is an effective treatment for complications of portal hypertension in hepatic myeloid metaplasia and improves nutritional status 47
Response to letter by Mookerjee and Jalan 46
Ruolo dell'elastografia transiente nell'identificazione della fibrosi in pazienti con epatopatia cronica HCV correlata 45
Curcumin limits the fibrogenic evolution of experimental steatohepatitis. Lab Invest. 2009 Nov 9. 44
Reply 39
Elastography for the non invasive assessment of liver disease: limitations and future. 39
Physical activity in liver transplant recipients: a large multicenter study 35
Oxidative stress–induced fibrinogen modifications in liver transplant recipients: unraveling a novel potential mechanism for cardiovascular risk 31
Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis 29
Management of a complex transjugular intrahepatic portosystemic shunt dysfunction with endotipsitis through rotational thrombectomy 28
Trichobezoar causing gastric outlet obstruction in a patient with trichotillomania 25
Reply 22
Reply to: "Post-TIPS OHE: Are we really making a mountain out of a molehill?" 16
Editorial: Looking at Neptune with a binocular 15
Reply to: “Hepatic encephalopathy and survival after transjugular intra-hepatic portosystemic shunt: Do spontaneous portosystemic shunts matter?” 15
Reply to: Does encephalopathy with early onset after TIPS impact on mortality? 14
Reply 14
Evaluating the predictive performance of the elderly patient calculator TIPS score in a North American cohort 12
Totale 9.031
Categoria #
all - tutte 24.397
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.397


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.077 0 0 0 0 174 173 168 188 150 77 114 33
2020/2021902 88 69 75 93 32 119 29 76 72 126 56 67
2021/2022595 25 55 38 20 22 28 31 27 34 42 114 159
2022/20231.635 146 267 56 136 119 288 215 94 196 13 49 56
2023/2024576 22 68 93 31 29 56 13 181 8 33 33 9
2024/20252.578 124 402 262 697 1.093 0 0 0 0 0 0 0
Totale 9.031